Cargando…

PD-1-mAb Plus Regimen in the First and Second Lines of Advanced and Unresectable Biliary Tract Carcinoma: A Real-World, Multicenter Retrospective Analysis

INTRODUCTION: Advanced biliary tract carcinoma (BTC) has a poor prognosis and few treatment options. We compared the efficacy of the PD-1 monoclonal antibody (PD-1-mAb) combined regimens with the standard chemotherapy in the first-line and second-line treatment of advanced BTC. METHODS: We retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Fang, Wang, Feng-Hua, Sun, Kaiyu, Jiang, Chang, Peng, Sui, Xu, Li-Xia, Kuang, Ming, Guo, Gui-Fang, Chen, Shu-Ling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635481/ https://www.ncbi.nlm.nih.gov/pubmed/36339826 http://dx.doi.org/10.2147/JIR.S364303

Ejemplares similares

SEPPA-mAb: spatial epitope prediction of protein antigens for mAbs
por: Qiu, Tianyi, et al.
Publicado: (2023)

Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor
por: Liu, Jingxian, et al.
Publicado: (2019)

Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma
por: Zhang, Jingzhe, et al.
Publicado: (2019)

Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

The Different Colors of mAbs in Solution
por: Ambrogelly, Alexandre
Publicado: (2021)

Correction: Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs
por: Fusco, Marnie L., et al.
Publicado: (2015)

Cellular tools for biosimilar mAb analysis
por: Lindemann, Carsten, et al.
Publicado: (2013)

Evolving trends in mAb production processes
por: Shukla, Abhinav A., et al.
Publicado: (2017)

State of the art in anti-cancer mAbs
por: Chiavenna, S. M., et al.
Publicado: (2017)

Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study
por: Zhang, Qiyi, et al.
Publicado: (2021)

Recent progress in the treatment for unresectable biliary tract cancer
por: Endo, Itaru
Publicado: (2023)

Stability enhancement in a mAb and Fab coformulation
por: Zhang, Hongyu, et al.
Publicado: (2020)

Pan-sarbecovirus mAb protects from variants
por: Flemming, Alexandra
Publicado: (2021)

A mAb for the detection of the antiretroviral drug emtricitabine
por: Youngpairoj, Ae S., et al.
Publicado: (2022)

Targeted Nanobubbles of PD-L1 mAb Combined with Doxorubicin as a Synergistic Tumor Repressor in Hepatocarcinoma
por: Chen, Yezi, et al.
Publicado: (2022)

Modulating the tumor microenvironment improves antitumor effect of anti-PD-L1 mAb in breast cancer
por: Li, Xiuying, et al.
Publicado: (2023)

Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis
por: Wei, Joe Q., et al.
Publicado: (2023)

A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer
por: Volovat, Simona Ruxandra, et al.
Publicado: (2020)

RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin
por: Chun, Jung Won, et al.
Publicado: (2021)

Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study
por: Zhao, Jie, et al.
Publicado: (2022)

A combination of anti‐PD‐L1 mAb plus Lm‐LLO‐E6 vaccine efficiently suppresses tumor growth and metastasis in HPV‐infected cancers
por: Lin, Po‐Lin, et al.
Publicado: (2017)

Norepinephrine inhibits CD8(+) T-cell infiltration and function, inducing anti-PD-1 mAb resistance in lung adenocarcinoma
por: Geng, Qishun, et al.
Publicado: (2023)

Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
por: Wu, Jia-Yi, et al.
Publicado: (2021)

Population pharmacokinetic models of anti-PD-1 mAbs in patients with multiple tumor types: A systematic review
por: Shang, Jingyuan, et al.
Publicado: (2022)

Conversion surgery for initially unresectable extrahepatic biliary tract cancer
por: Oh, Moon Young, et al.
Publicado: (2021)

Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results
por: Ueno, Makoto, et al.
Publicado: (2020)

Novel strategy for a high-yielding mAb-producing CHO strain (overexpression of non-coding RNA enhanced proliferation and improved mAb yield)
por: Tabuchi, Hisahiro
Publicado: (2013)

Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers
por: Ba, Hongping, et al.
Publicado: (2023)

Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer
por: Zhu, Chengpei, et al.
Publicado: (2023)

Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial
por: Kim, Seung Tae, et al.
Publicado: (2019)

Treatment of Marmoset Intracerebral Hemorrhage with Humanized Anti-HMGB1 mAb
por: Wang, Dengli, et al.
Publicado: (2022)

Comparison of two transarterial chemoembolization regimens in patients with unresectable hepatocellular carcinoma: raltitrexed plus oxaliplatin versus 5-fluorouracil plus oxaliplatin
por: Cui, Wei, et al.
Publicado: (2017)

New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC
por: Lembo, Rosa Rapuano, et al.
Publicado: (2022)

A Double-Layered Covered Biliary Metal Stent for the Management of Unresectable Malignant Biliary Obstruction: A Multicenter Feasibility Study
por: Park, Jin-Seok, et al.
Publicado: (2016)

On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer
por: Correale, Pierpaolo, et al.
Publicado: (2020)

Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling
por: Passariello, Margherita, et al.
Publicado: (2019)

Developmental changes in heparan sulfate expression: in situ detection with mAbs
Publicado: (1992)

Direct analysis of mAb aggregates in mammalian cell culture supernatant
por: Paul, Albert J, et al.
Publicado: (2014)

Conservancy of mAb Epitopes in Ebolavirus Glycoproteins of Previous and 2014 Outbreaks
por: Ponomarenko, Julia, et al.
Publicado: (2014)

Self-Interaction Chromatography of mAbs: Accurate Measurement of Dead Volumes
por: Hedberg, S. H. M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kkjnn2r6q4tqgc51qvhss7lpqb